Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine for Major Depressive Episodes in Schizophrenia
NCT01822418Phase 4Completed
- Sponsor
- Central Institute of Mental Health
- Start
- Jan 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Central Institute of Mental Health. Primary endpoint: Antidepressive efficacy at 6 weeks. Started Jan 2013; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01822418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01822418.